share_log

Replimune Begins RP2 Clinical Trials With First Patients Enrolled In Metastatic Uveal Melanoma And Hepatocellular Carcinoma

Replimune Begins RP2 Clinical Trials With First Patients Enrolled In Metastatic Uveal Melanoma And Hepatocellular Carcinoma

Replimune開始進行RP2臨牀試驗,首批患者已在轉移性葡萄膜黑色素瘤和肝細胞癌中入組。
Benzinga ·  01/08 21:08

Advancing Its Oncolytic Immunotherapy Platform Following RP1 BLA Submission And Breakthrough Therapy Designation

在提交RP1生物製劑許可申請和突破性療法認定後,推進其溶瘤免疫療法平台

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論